ge

Analyst upgrades:

• Citigroup upgraded Vistaprint (VPRT) to buy from hold on valuation following the recent pullback in shares. The firm also raised its price target on the stock to $62 from $55.
• Fox-Pitt upgraded Eaton Vance (EV) to outperform from in line citing strong fundamentals. The firm raised its target to $36 from $34.
• Stifel Nicolaus upgraded Hospitality Properties (HPT) to buy from hold citing valuation and expected cash dividend in 2010. The firm has a $22 target on the stock.
• The Advisory Board (ABCO) was upgraded to overweight from equal weight at First Analysis.
• Technip (TKPPY) was upgraded to outperform from neutral at Credit Suisse.
• Jefferies upgraded Energy XXI (EXXI) to hold from underperform and raised its target to $2 from $1.

Analyst upgrades:

• Wells Fargo upgraded Prudential (PRU) to outperform from market perform. The firm thinks the company is in a better position than its peers and will be able to more effectively exploit M&A opportunities.
• UBS upgraded Reliance Steel (RS) to buy from neutral based on potential growth through M&A and valuation. The firm raised its target to $50 from $49.
• Deutsche Bank upgraded Eastman Chemical (EMN) to buy from hold on expectations the company's portfolio transformation will drive higher normalized earnings power, which the firm believes is not fully reflected in consensus estimates. Deutsche raised its target price on shares to $70 from $62.
• Amylin Pharma (AMLN) was upgraded to overweight from equal weight at Barclays.
• Cephalon (CEPH) was upgraded to buy from hold at Jefferies.
• Acuity Brands (AYI) was upgraded to outperform from perform at Oppenheimer.

Analyst upgrades:

• Jefferies upgraded Starbucks (SBUX) to buy from hold, citing EPS and revenue momentum heading into 2010. The firm raised its target to $25 from $22.
• Soleil upgraded Zions Bancorp (ZION) to buy from hold on valuation as it believes the recent pullback provides an attractive entry point. The firm has a $17.50 price target on shares.
• RBC Capital expects Rigel Pharmaceuticals (RIGL) to sign a partnership for R788 in the next four months to run its global Phase III program. Shares were upgraded to outperform from sector perform and its target was raised to $11 from $9.
• Deere (DE) was upgraded to overweight from equal weight at Morgan Stanley.
• Shire (SHPGY) was raised to outperform from market perform at Bernstein.
• Ann Taylor (ANN) was upgraded to overweight from market weight at Thomas Weisel.
• J.M. Smucker (SJM) was upgraded to overweight from neutral at JPMorgan.

TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all.

Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (MRK) (Cramer's Take), Bristol-Myers (BMY) (Cramer's Take) and Lilly (LLY) (Cramer's Take). But there is one drug stock that is continually met with skepticism -- Sanofi Aventis (SNY) (Cramer's Take), the French vaccine and pharmaceutical maker run by Christian Viehbacher. The resistance is obvious, as his biggest two drugs are coming off patent very soon, and his hope is that by 2013 the company might again reach 2008 levels.

Sounds like there's no reason to buy this one. Sounds like its 4% dividend isn't safe.

Analyst upgrades:

• Pali Capital upgraded Lazard (LAZ) to buy from neutral, citing a healthy restructuring environment, improving M&A and strength in the asset management segment. The firm has a $46 target on shares.
• Baird upgraded Scansource (SCSC) to outperform from neutral, citing strength in the channel business and growth drivers from improved telephony and security. The firm has a $30 target on shares.
• Citigroup upgraded Liberty Interactive (LINTA) to buy from hold, citing the company's QVC unit's return to growth. The firm raised its target on shares to $13.25 from $12.
• Hess Corp (HES) was upgraded to overweight from equal weight at Morgan Stanley.
• Vulcan Materials (VMC) was upgraded to buy from neutral at UBS.
• Dillard's (DDS) was upgraded to buy from hold at Deutsche Bank.

Analyst upgrades:

• Oppenheimer upgraded Momenta Pharmaceuticals (MNTA) to outperform from perform as it finds the stock attractive ahead of FDA's decision on M-enoxaparin. The firm has a $15 price target on the stock.
• Wells Fargo upgraded Symmetry Medical (SMA) to market perform from underperform. The firm cited several factors for the upgrade, including valuation and its belief that Symmetry's customers have begun to deplete their inventories.
• Piper Jaffray upgraded Myriad Pharmaceuticals (MYRX) to neutral from underweight after the company announced Phase 2a date for Azixa. The firm has a $5 price target on shares.
• AvalonBay (AVB) and Mid-America Apartment (MAA) were upgraded to outperform from sector perform at RBC Capital.
• GSI Commerce (GSIC) was upgraded to overweight from equal weight at Morgan Stanley.
• FICO (FICO) was upgraded to equal weight from Underweight at Stephens.

TheStreet.com's Jim Cramer says the world's economies are getting too strong to obey these downgrades of Intel and TI.

When Wall Street starts looking at tech companies as they would industrials -- as they should be scrutinized -- then we will not get downgrades like Bank of America/Merrill's takedowns of Intel (INTC) (Cramer's Take) and Texas Instruments (TXN) (Cramer's Take).

The essence of these two downgrades is the looming inventory correction that everyone has feared from $14 a share onward for Intel and $18 for Texas Instruments at the start of the summer. At every step I have heard of this coming breakdown, the double ordering and the decline in demand as one analyst after another has warned us of the apocalypse around the corner.

Analyst upgrades:

• RBC Capital upgraded Fidelity National (FIS) to outperform from sector perform. The firm upgraded the stock due to valuation, and its belief that the company will clear up issues related to its merger on its Analyst Day, scheduled for Dec. 7. The firm set a $28 target on the stock.
• Citigroup upgraded Smith International (SII) to buy from hold, citing the sell-off in shares following its 28M share equity offering. Note that Smith International priced 28M shares Tuesday at $26.50.
• Wells Fargo upgraded DynCorp (DCP) to outperform from market perform. The firm upgraded the stock on valuation, and because it believes that the impact on DynCorp of a possible indictment of PWC will be minimal, if any.
• Rockwell (ROK) was upgraded to overweight from neutral at HSBC.
• Omega Healthcare (OHI) was upgraded to outperform from market perform at JMP Securities.
• Analog Devices (ADI) was upgraded to conviction buy from buy at Goldman.

Analyst upgrades:

• Barclays upgraded Exxon (XOM) to overweight from equal weight based on a higher production growth outlook. The firm, which raised its target to $92 from $90, expects Exxon to have organic growth of more than 3% in 2010 and an average growth rate of 2.6% between 2009 and 2013.
• Kaufman Bros. upgraded Palm (PALM) to buy from hold citing the recent pullback in shares and indications that Verizon (VZ) will carry webOS phones as early as 1H10. The firm has a $16 target on the stock.
• Piper Jaffray raised Medicis (MRX) to neutral from underweight and raised its target to $20 from $16. Following a management meeting, Piper said they have increased confidence in Soldyn risk and LipoSonix's safety profile.
• Illinois Tool Works (ITW) was upgraded to buy from neutral at UBS.
• Devon Energy (DVN) was upgraded to outperform from market perform at Wells Fargo.
• Carmike Cinemas (CKEC) was upgraded to buy from neutral at Merriman.

Sprint Nextel (S) reported this morning that it paid off an outstanding loan worth $1 billion on its $4.5 billion revolving credit facility. As a result, the wireless company no longer has an outstanding balance on its revolving credit facility. At the end of the third quarter, Sprint had $5.9 billion on hand in cash, cash equivalents, and short-term investments, plus $1.6 billion in borrowing capacity under its revolving bank credit facility.

In other Sprint news this morning, Sprint shares were upped from "neutral" to "outperform" at Credit Suisse. Analyst Jonathan Chaplin set his price target at $6, asserting that the company will benefit from cost cutting, stronger sales of prepaid service, and improved customer retention trends. Sprint's stock settled Friday at $3.10, so Chaplin's price target implies expected upside of nearly 94%.

Analyst upgrades:

• Credit Suisse upgraded Sprint Nextel (S) to outperform from neutral and raised its target to $6 from $4. The firm believes Sprint Nextel's core business is turning and that valuation is attractive. Credit Suisse also added Sprint Nextel to its Focus List.
• Goldman expects Nordstrom (JWN) to benefit from a recovery in the high-end consumer. The firm upgraded shares to buy from neutral and raised its target to $41 from $39.
• Deutsche Bank remains cautious on the Dry Bulk sector long-term but expects increased Q4 day rates. The firm upgraded Genco (GNK) to buy from hold and raised its target to $31 from $24; the firm also upgraded Eagle Bulk (EGLE) to hold from sell.
• Steelcase (SCS) was upgraded to buy from hold at BB&T.
• United Rentals (URI) was upgraded to outperform from perform at Oppenheimer.
• GLG Partners (GLG) was upgraded to outperform from market perform at Keefe Bruyette.
• Ladish (LDSH) was upgraded to outperform from market perform at FBR Capital.

Analyst upgrades:

• Wells Fargo upgraded Qualcomm (QCOM) to outperform from market perform. The firm believes key risks have been eliminated, such as the license dispute with Nokia (NOK) and litigation with Broadcom (BRCM), and thinks Qualcomm is well-positioned for handset unit shipments growth. Wells has a $50 to $60 target range on shares.
• Oppenheimer upgraded Juniper Networks (JNPR) to outperform from perform as it views shares as compelling at current levels and thinks the company is well positioned for 2010. Opco set a $31 price target on the stock.
• FBR Capital upgraded Frontline (FRO) to outperform from market perform after raising its rating on the tanker industry to overweight. The firm raised its target on shares to $33 from $23.
• PetSmart (PETM) was upgraded to buy from neutral at Goldman.
• Career Education (CECO) was upgraded to equal weight from underweight at Barclays.
• Rosetta Resources (ROSE) was upgraded to buy from neutral at SunTrust.

Analyst upgrades:

• Goldman upgraded Aeropostale (ARO) to neutral from sell. The firm, which has a $34 target on the stock, cites the recent sell-off in shares for the upgrade.
• Janney Montgomery upgraded Consolidated Water (CWCO) to buy from neutral on valuation and on expectations the company's earnings will recover in 2010. The firm has a $15 target on the stock.
• Wunderlich upgraded Transmontaigne Partners (TLP) to buy from hold on valuation as it believes the sell-off on the company's Q3 results is overdone. The firm keeps a $26.50 price target on the stock.
• Mobile TeleSystems (MBT) was upgraded to buy from neutral at UBS.
• HSBC (HBC) was raised to buy from hold at Societe Generale.
• Redwood Trust (RWT) was upgraded to outperform from market perform at JMP Securities.

Analyst upgrades:

• Citigroup upgraded FPL Group (FPL) to buy from hold on valuation and recommends buying the stock into the staff recommendation. The firm raised its target on shares to $58 from $55.
• Deutsche Bank upgraded Smithfield Foods (SFD) to buy from hold as it believes the company's fundamentals and export demand outlook are improving. The firm raised its target on shares to $20 from $12.
• Credit Suisse upgraded T. Rowe Price (TROW) to outperform from neutral and raised its target to $60 from $55 based on strong net inflows and potential operating leverage.
• Microchip (MCHP) was upgraded to neutral from sell at Goldman.
• Toll Brothers (TOL) was upgraded to outperform from market perform at Wells Fargo.
• Ascent Solar (ASTI) was upgraded to hold from underperform at Jefferies.

Notorious insurance titan American International Group (AIG) is on the upswing today, after Moody's Investors Service reported late Monday that it expects AIG will be able to repay its government debt. The ratings agency observed that AIG has made progress with its restructuring plan, and the firm's latest quarterly earnings "show continued stabilization of the core insurance operations despite challenging market conditions."

The insurance issue has put many of its non-core assets up for sale during the past year to generate capital and pare its unwieldy size, but some of those plans have been iced by new CEO Robert Benmosche. Moody's likes the new chief's approach, with the firm observing, "We believe that the slower approach to restructuring could help AIG to generate more favorable values from its business portfolio than would be the case under rushed asset sales."